Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for scalp hypothermia during chemotherapy to prevent hair loss, effective May 15, 2026. Here's what changes for billing teams.
CMS scalp hypothermia coverage policy has been updated. The Centers for Medicare & Medicaid Services revised its national position on scalp cooling systems used during chemotherapy to reduce chemotherapy-induced alopecia. No policy code has been assigned to this coverage policy. The full source document is available at the CMS policy page. This post covers what billing teams and revenue cycle professionals need to know before the May 15, 2026 effective date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | Scalp Hypothermia During Chemotherapy to Prevent Hair Loss |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | 2026-05-15 |
| Impact Level | Medium |
| Specialties Affected | Medical Oncology, Hematology/Oncology, Infusion Centers, Hospital Outpatient |
| Key Action | Audit your scalp hypothermia billing workflows and confirm documentation meets the updated medical necessity criteria before May 15, 2026 |
CMS Scalp Hypothermia Coverage Criteria and Medical Necessity Requirements 2026
CMS has a specific history with scalp cooling. In 2017, CMS issued a National Coverage Determination (NCD) that covered scalp hypothermia — also called scalp cooling — for Medicare beneficiaries undergoing chemotherapy for solid tumor cancers. That NCD was a meaningful shift. Before it, most Medicare patients couldn't get coverage for scalp cooling at all.
The 2026 modification builds on that foundation. The core coverage policy for scalp hypothermia remains tied to medical necessity: the patient must have a solid tumor cancer and be actively receiving chemotherapy. Coverage does not extend to patients receiving chemotherapy for hematologic malignancies. That distinction has not changed, and it remains one of the most common sources of claim denial in this category.
Medical necessity documentation is non-negotiable here. Your oncologist or treating physician needs to clearly document the cancer diagnosis, the chemotherapy regimen, and the clinical rationale for scalp cooling. Vague documentation is what gets these claims kicked back. The payer wants to see that this isn't cosmetic — it's a quality-of-life intervention for a patient actively under treatment.
Prior authorization requirements under this policy vary by Medicare Administrative Contractor (MAC). Some MACs have issued local coverage determinations (LCDs) layered on top of the national policy. Check with your specific MAC before billing. If you're not sure whether your MAC has an active LCD for scalp hypothermia, call them directly or check the LCD database on the CMS website.
This coverage policy does not list specific CPT or HCPCS codes in the policy data available for this post. Billing teams should refer to their MAC's billing guidelines and the FDA-cleared device manufacturer's guidance for the correct codes currently in use for scalp cooling system reimbursement.
CMS Scalp Hypothermia Exclusions and Non-Covered Indications
The coverage exclusions here are real and clinically specific. CMS does not cover scalp hypothermia for patients being treated for hematologic cancers — leukemia, lymphoma, and multiple myeloma are the most common examples. The clinical rationale is that circulating cancer cells in the bloodstream could theoretically shelter in the scalp during cooling, reducing treatment effectiveness. That concern doesn't apply the same way to solid tumors.
Cosmetic use is also excluded. If the documentation frames the procedure as primarily cosmetic or elective rather than a direct adjunct to chemotherapy, expect a claim denial. The clinical note needs to be explicit about the treatment context.
Scalp cooling outside of an active chemotherapy session is not covered. The device has to be used in conjunction with the infusion — not as a standalone service. If your billing team separates the scalp cooling charge from the chemotherapy encounter, that's a red flag for auditors. Keep these services tied together in your documentation and claim submission.
Finally, devices that are not FDA-cleared for scalp hypothermia during chemotherapy fall outside this coverage policy entirely. CMS coverage is contingent on using an approved system. If a patient brings in an unapproved device, you have a billing problem before the claim is even submitted.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Solid tumor cancer patient receiving chemotherapy | Covered | Not specified in policy data | Medical necessity documentation required; check MAC for LCD and prior auth requirements |
| Hematologic malignancy (leukemia, lymphoma, multiple myeloma) | Not Covered | Not specified in policy data | Excluded due to risk of circulating tumor cells in scalp during cooling |
| Cosmetic or elective use outside chemotherapy context | Not Covered | Not applicable | Documentation must frame service as adjunct to active chemotherapy |
| Scalp cooling outside of active chemotherapy session | Not Covered | Not applicable | Must occur during infusion encounter; do not bill as standalone service |
| Use of non-FDA-cleared scalp cooling device | Not Covered | Not applicable | CMS coverage requires FDA-cleared device |
CMS Scalp Hypothermia Billing Guidelines and Action Items 2026
Here's what your billing team needs to do before May 15, 2026.
| # | Action Item |
|---|---|
| 1 | Confirm your MAC's current LCD. Not every MAC handles scalp hypothermia the same way. Pull your MAC's LCD for scalp cooling before the effective date. If your MAC has updated its local guidance to align with or extend the CMS modification, your billing guidelines may have changed at the regional level too. |
| 2 | Audit your documentation templates. Your oncology team's notes need to clearly document the cancer diagnosis as a solid tumor, the chemotherapy regimen, and the clinical rationale for scalp cooling. If your current templates don't capture that, update them before May 15, 2026. Incomplete documentation is the fastest route to claim denial. |
| 3 | Verify the FDA-cleared device being used. Check that the scalp cooling system in your infusion center is FDA-cleared for chemotherapy-induced alopecia prevention. Keep that documentation in your compliance file. If a claim is audited, you'll need it. |
| 4 | Confirm current CPT and HCPCS codes with your MAC. This coverage policy does not list specific codes in the available policy data. Scalp hypothermia billing has historically used specific HCPCS codes, but the correct codes for your setting depend on MAC guidance and the device being used. Don't assume last year's codes still apply — confirm them now. |
| 5 | Separate cosmetic from clinical in your charge capture. Make sure your charge capture process flags scalp cooling as a clinical service tied to chemotherapy — not a separate, standalone cosmetic service. This distinction matters both for claim submission and for any post-payment audit. |
| 6 | Check prior authorization requirements. Prior authorization for scalp hypothermia is not universally required under Medicare, but some MACs and Medicare Advantage plans have separate rules. If your practice treats Medicare Advantage patients, check each plan individually. A missed prior auth is an automatic denial. |
| 7 | Brief your infusion center billing staff. The people billing these claims need to know what changed. Schedule a short review before May 15, 2026. Even a 15-minute walkthrough of the updated criteria will reduce downstream denials. |
If your practice has significant volume in this category and you're unsure how the modification affects your specific payer mix, talk to your compliance officer before the effective date. The financial exposure is real — scalp cooling devices are expensive, reimbursement is tied to documentation, and a denial pattern here is hard to reverse retroactively.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Scalp Hypothermia Under CMS Coverage Policy
Covered CPT and HCPCS Codes
This coverage policy does not list specific CPT or HCPCS codes in the policy data available for this post. CMS scalp hypothermia billing has historically used HCPCS codes for the scalp cooling device and/or service, but the exact codes depend on your MAC's billing guidelines and the specific FDA-cleared device in use.
Contact your MAC directly to confirm the current billing codes before submitting claims under this modified policy. Do not use codes from prior years without confirming they remain active and applicable.
ICD-10-CM Diagnosis Codes
No specific ICD-10 codes are listed in the available policy data. Diagnosis codes should reflect the patient's solid tumor cancer diagnosis and should support medical necessity for scalp hypothermia in the context of active chemotherapy. Use the most specific ICD-10-CM code for the confirmed cancer diagnosis.
Do not use hematologic malignancy diagnosis codes to support scalp hypothermia claims — those indications are excluded under this coverage policy.
What This Policy Modification Means for Your Revenue Cycle
The real issue here is documentation consistency across your oncology team. CMS has been covering scalp hypothermia since 2017. This modification doesn't represent a dramatic reversal — but modifications exist for a reason. Something in the coverage policy language has changed, whether that's a clarification of criteria, an adjustment to coverage language, or a shift in how medical necessity is defined.
Until the full updated policy text is published and accessible, billing teams should treat this as a signal to tighten up existing workflows rather than wait for a detailed breakdown. The exclusions are clear. The documentation requirements have always been strict. The gap between covered and denied in this category is almost always a documentation gap — not a clinical one.
Scalp cooling reimbursement is modest relative to the chemotherapy services it accompanies, but denials add up. More importantly, a pattern of denials in this category can trigger broader audits of your oncology billing. That's not a risk worth taking over documentation shortcuts.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.